Marcia Bolton Hanson

US Patent:

51205351, Jun 9, 1992

Filed:

May 4, 1987

Appl. No.:

7/046846

Inventors:

Hans Marquardt - Mercer Island WA
Joyce M. Zarling - Seattle WA
Mohammed Shoyab - Seattle WA
Marcia B. Hanson - Seattle WA
Mario N. Lioubin - Bellevue WA
Thomas J. Brown - Seattle WA
Tatsuhiko Ikeda - Kobe, JP

Assignee:

Oncogen - Seattle WA

International Classification:

A61K 3702
A61K 3766
A61K 4505

US Classification:

424 855

Abstract:

Novel compositions are provided for modulating growth, particularly of tumor cells, which compositions are combinations of Oncostatin M, and one or both of transforming growth factors or. gamma. -interferons, or analogs thereof. In addition, a novel transforming growth factor is provided, designated TGF-. beta. 2, as well as methods for its preparation.

US Patent:

56187157, Apr 8, 1997

Filed:

Jun 10, 1993

Appl. No.:

8/075199

Inventors:

Mohammed Shoyab - Seattle WA
Joyce M. Zarling - Seattle WA
Hans Marquardt - Mercer Island WA
Marcia B. Hanson - Seattle WA
Najma Malik - Seattle WA
Peter S. Linsley - Seattle WA
Timothy M. Rose - Seattle WA
Anthony F. Purchio - Seattle WA

Assignee:

Oncogen Limited Partnership - Seattle WA

International Classification:

C12N 500
C12N 1500
C12P 2106
C07H 1700

US Classification:

435325

Abstract:

Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.

US Patent:

54515068, Sep 19, 1995

Filed:

Jun 16, 1993

Appl. No.:

8/078707

Inventors:

Mohammed Shoyab - Seattle WA
Joyce M. Zarling - Seattle WA
Hans Marquardt - Mercer Island WA
Marcia B. Hanson - Seattle WA
Peter S. Linsley - Seattle WA

Assignee:

Oncogen Limited Partnership - Seattle WA

International Classification:

G01N 3374
G01N 3368
G01N 3360
C07K 1300

US Classification:

435 723

Abstract:

Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.

US Patent:

54280125, Jun 27, 1995

Filed:

Jul 1, 1993

Appl. No.:

8/085279

Inventors:

Mohammed Shoyab - Seattle WA
Joyce M. Zarling - Seattle WA
Hans Marquardt - Mercer Island WA
Marcia B. Hanson - Seattle WA
Thomas J. Brown - Poulsbo WA

Assignee:

Oncogen Limited Partnership - Seattle WA

International Classification:

C12P 2102
A61K 3702
C12N 1500

US Classification:

514 12

Abstract:

Novel compositions comprising Oncostatin M and congeners thereof, as well as methods for their preparation and methods for their use are provided. The compositions may be prepared by isolation from natural sources, or by recombinant means in either prokaryotic or eukaryotic host cells. In addition, the DNA and polypeptide sequences for Oncostatin M are disclosed. The compositions find use in modulating growth of cells, in particular inhibition of tumor cell proliferation, and stimulation of normal cell growth, especially cells involved in hematopoiesis. Cell growth inhibition compositions may additionally include an adjunctive agent comprising at least one of a transforming growth factor, tumor necrosis factor, or an interferon. Receptors having high affinity for Oncostatin M may additionally be used to screen polypeptides for Oncostatin M-like activity. Methods for use of antibodies to the compositions and probes specific for Oncostatin M mRNA as a means for detecting tumor cells are also provided.